KAHR’s Anti-CD47 in Blood Cancers Clinical Trials Funded by Texas MD Anderson Cancer Focus Fund
KAHR, a Jerusalem based clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of…
Continue Reading
KAHR’s Anti-CD47 in Blood Cancers Clinical Trials Funded by Texas MD Anderson Cancer Focus Fund